# Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

Study · id `cardio:ct-nct03068130` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03068130](<https://clinicaltrials.gov/study/NCT03068130>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03068130

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 261 participants.

## Technical summary

Registry record NCT03068130. Allocation not applicable; no masking; primary purpose treatment. Start 2017-04-18 (actual); primary completion 2020-09-30 (actual). Results posted on 2023-10-12.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 261 participants (enrolled count; ClinicalTrials.gov record NCT03068130, source copy `cardio:ctgov-nct03068130-2025-06-11`, retrieved 2026-10-31)
- Started: 2017-04-18 (actual) (ClinicalTrials.gov record NCT03068130, source copy `cardio:ctgov-nct03068130-2025-06-11`, retrieved 2026-10-31)
- Primary completion: 2020-09-30 (actual) (ClinicalTrials.gov record NCT03068130, source copy `cardio:ctgov-nct03068130-2025-06-11`, retrieved 2026-10-31)
- Completion: 2020-09-30 (actual) (ClinicalTrials.gov record NCT03068130, source copy `cardio:ctgov-nct03068130-2025-06-11`, retrieved 2026-10-31)
- Results first posted: 2023-10-12 (ClinicalTrials.gov record NCT03068130, source copy `cardio:ctgov-nct03068130-2025-06-11`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Czechia; Germany; Israel; Japan; Mexico; Netherlands; Philippines; Spain; United Kingdom (ClinicalTrials.gov record NCT03068130, source copy `cardio:ctgov-nct03068130-2025-06-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03068130-2025-06-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
- Acronym: RANGER
- Condition: Pulmonary Hypertension
- Intervention (Drug): Bardoxolone methyl
- Lead sponsor: Biogen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Biogen (`cardio:org-biogen`)

## Provenance

Content hash: 7b2b69098925fc7aa98486cdd641a591c098cd1fc584a6b5f50f6d19a0a9b88c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
